SAA1 and hereditary elliptocytosis: When disregarding vaccine treatment, plotting SAA1, IP-10, and IL-6 ratios, and illustrating 3BM in a heatmap by those that reach a premature humane endpoint (HE) versus those that survive up to a year postinfection (endpoint by experimental study design, EE), significant diagnostic positivity at early time points predicts the outcome of experimental infection at the longer term (Figure 5 and Figure S9).